CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 12, 2006--Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that it has enrolled and treated the first patient in a phase I/II clinical study of romidepsin in combination with gemcitabine to treat pancreatic cancer and other solid tumors.
